Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
San Gabriel Valley Index
San Gabriel Valley
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Intra-Cellular Ther
(NQ:
ITCI
)
72.42
-0.24 (-0.33%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Sep 5, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Intra-Cellular Ther
< Previous
1
2
3
4
5
Next >
Intra-Cellular Therapies's Earnings: A Preview
November 02, 2022
Intra-Cellular Therapies (NASDAQ:ITCI) is set to give its latest quarterly earnings report on Thursday, 2022-11-03. Here's what investors need to know before the announcement. Analysts estimate that...
Via
Benzinga
Looking Into Intra-Cellular Therapies's Return On Capital Employed
September 02, 2022
Intra-Cellular Therapies (NASDAQ:ITCI) brought in sales totaling $55.58 million during Q2 according to data provided by Benzinga Pro. However, earnings decreased 20.08%, resulting in a loss of $86.60...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 22, 2022
August 22, 2022
Upgrades
Via
Benzinga
Illumina, Poshmark, Olo And Some Other Big Losers From Friday
August 15, 2022
U.S. stocks closed higher on Friday, with the Dow Jones gaining more than 400 points. Here is the list of some big stocks moving lower in the previous session.
Via
Benzinga
Where Intra-Cellular Therapies Stands With Analysts
August 11, 2022
Within the last quarter, Intra-Cellular Therapies (NASDAQ:ITCI) has observed the following analyst ratings:
Via
Benzinga
Robust Uptake Of Antipsychotic Drug Boosts Intra-Cellular's Q1 Earnings
May 10, 2022
Via
Benzinga
Earnings Scheduled For March 1, 2022
March 01, 2022
Companies Reporting Before The Bell • Precigen (NASDAQ:PGEN) is expected to report earnings for its fourth quarter. • TG Therapeutics (NASDAQ:TGTX) is estimated...
Via
Benzinga
Biotech Daily: Regulatory Setback For CorMedix, Mersana & GSK In Cancer Pact, BARDA Funding For Opioid Overdose Hopeful
August 09, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Intra-Cellular Therapies: Q2 Earnings Insights
August 09, 2022
Intra-Cellular Therapies (NASDAQ:ITCI) reported its Q2 earnings results on Tuesday, August 9, 2022 at 08:00 AM. Here's what investors need to know about the announcement.
Via
Benzinga
Analyst Ratings for Intra-Cellular Therapies
July 07, 2022
Over the past 3 months, 4 analysts have published their opinion on Intra-Cellular Therapies (NASDAQ:ITCI) stock. These analysts are typically employed by large Wall Street banks and tasked with...
Via
Benzinga
INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Intra-Cellular Therapies, Inc. with Losses to Contact the Firm
June 16, 2022
From
The Schall Law Firm
Via
Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For July 7, 2022
July 07, 2022
Upgrades
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For June 14, 2022
June 14, 2022
Upgrades
Via
Benzinga
Looking Into Intra-Cellular Therapies's Return On Capital Employed
June 09, 2022
According to Benzinga Pro data, during Q1, Intra-Cellular Therapies (NASDAQ:ITCI) posted sales of $35.00 million. Earnings were up 15.88%, but Intra-Cellular Therapies still reported an overall loss of...
Via
Benzinga
Intra-Cellular Therapies Stock Clears Technical Benchmark, Hitting 90-Plus RS Rating
May 11, 2022
Intra-Cellular Therapies stock cleared a key performance benchmark, with its Relative Strength (RS) Rating, rising to 97.
Via
Investor's Business Daily
103 Biggest Movers From Yesterday
May 11, 2022
Gainers
Via
Benzinga
77 Stocks Moving In Tuesday's Mid-Day Session
May 10, 2022
Gainers
Via
Benzinga
The Daily Biotech Pulse: Pfizer Acquires Migraine Drugmaker For $11B, Biogen Files For Second Alzheimer's Drug Approval, Longeveron CEO Leaves
May 10, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Recap: Intra-Cellular Therapies Q1 Earnings
May 10, 2022
Intra-Cellular Therapies (NASDAQ:ITCI) reported its Q1 earnings results on Tuesday, May 10, 2022 at 08:00 AM. Here's what investors need to know about the announcement.
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For April 22, 2022
April 22, 2022
Upgrades
Via
Benzinga
What 4 Analyst Ratings Have To Say About Intra-Cellular Therapies
April 21, 2022
Analysts have provided the following ratings for Intra-Cellular Therapies (NASDAQ:ITCI) within the last quarter:
Via
Benzinga
Stocks That Hit 52-Week Highs On Thursday
April 07, 2022
On Thursday, 75 stocks made new 52-week highs. Interesting Highlights From Today's 52-Week Highs: The largest company by market cap to hit a new 52-week high...
Via
Benzinga
Intra-Cellular Therapies's Return On Capital Employed Insights
March 04, 2022
Intra-Cellular Therapies (NASDAQ:ITCI) brought in sales totaling $25.67 million during Q4 according to data provided by Benzinga Pro. However, earnings decreased 11.48%, resulting...
Via
Benzinga
What 6 Analyst Ratings Have To Say About Intra-Cellular Therapies
March 02, 2022
Analysts have provided the following ratings for Intra-Cellular Therapies (NASDAQ:ITCI) within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish...
Via
Benzinga
Intra-Cellular Therapies: Q4 Earnings Insights
March 01, 2022
Intra-Cellular Therapies (NASDAQ:ITCI) reported its Q4 earnings results on Tuesday, March 1, 2022 at 08:00 AM. Here's what investors need to know about the announcement...
Via
Benzinga
The Daily Biotech Pulse: Legend Biotech, CTI Biopharma Receive FDA Approvals, AbbVie Announces Delay In Skyrizi Review, Editas Gains On CRISPR Patent Resolution
March 01, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Editas Gains On Resolution Of CRISPR Gene Editing Patent Case Editas Medicine...
Via
Benzinga
The Week Ahead In Biotech (Feb. 27-March 5): Earnings, Multiple Regulatory Decisions Take The Spotlight
February 27, 2022
Biopharma stocks lock-stepped with the broader market in the week ending Feb. 25 before finishing higher. The trajectory was the same, with the sector declining in the first...
Via
Benzinga
Where Intra-Cellular Therapies Stands With Analysts
February 16, 2022
Analysts have provided the following ratings for Intra-Cellular Therapies (NASDAQ:ITCI) within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish...
Via
Benzinga
Expert Ratings For Intra-Cellular Therapies
February 16, 2022
Within the last quarter, Intra-Cellular Therapies (NASDAQ:ITCI) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish...
Via
Benzinga
Intra-Cellular Therapies Inc.: The Winning Streak Continues
February 16, 2022
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. Intra-Cellular Therapies Inc. (NASDAQ:...
Via
Benzinga
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.